VivoSeq
Infectious Disease

Bacterial Conjunctivitis

24

Pipeline Programs↗

2

Active Trials↗

11

Companies Involved↗

Bacterial Conjunctivitis is an emerging landscape with 24 programs across 11 companies. The most active players are IVIEW Therapeutics Inc., Takeda, Baxis Pharmaceuticals, Inc.. 3 therapies are approved with 17 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

86/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

IVIEW Therapeutics Inc.

2 programs

Phase 2Takeda logo

Takeda

2 programs

Phase 3B

Baxis Pharmaceuticals, Inc.

1 program

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 3V

Viatris Specialty LLC

1 program

Phase 3Bayer logo

Bayer

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

32

clinical trials

Completed24 · 75%
Terminated3 · 9%
Unknown status2 · 6%
Recruiting2 · 6%
Withdrawn1 · 3%

Clinical Trials

Trial Activity

32 trials

Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
Recruiting·BBaxis Pharmaceuticals, Inc.·Phase 3·NCT06911424·400 enrolled
A Phase I/II Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SUM-191 in Healthy Participants and in Participants With Bacterial Conjunctivitis
Recruiting·SSenju USA, Inc.·Preclinical·NCT07565103·426 enrolled
An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
Completed·AAlcon Research·Phase 3·NCT01573910·985 enrolled
Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis
Completed·AAlcon Research·Phase 3·NCT00759148·1,179 enrolled
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00105469·743 enrolled
Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.
Completed·LLaboratoires Thea·Phase 3·NCT01155999·286 enrolled
Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
Completed·AAlcon Research·Phase 4·NCT00798577·24 enrolled
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
Completed·BBausch & Lomb Incorporated·Phase 2/3·NCT00972777·474 enrolled
AL-15469A for the Treatment of Bacterial Conjunctivitis
Completed·AAlcon Research·Phase 3·NCT00332293·695 enrolled
AL-15469A for the Treatment of Bacterial Conjunctivitis
Completed·AAlcon Research·Phase 3·NCT00331916·600 enrolled
Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
Completed·AAlcon Research·Phase 4·NCT00312338·137 enrolled
A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.
Completed·BBausch & Lomb Incorporated·Phase 3·NCT00347932·957 enrolled
Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis
Completed·LLaboratoires Thea·Phase 3·NCT00357773
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
Completed·Takeda logoTakeda·Phase 3·NCT03004924·753 enrolled
Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
Completed·LLaboratorios Sophia S.A de C.V.·Phase 2·NCT02980523·150 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)